Pressure BioSciences Revenue and Competitors

Boston, MA USA

Location

#7497

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Pressure BioSciences's estimated annual revenue is currently $3.5M per year.(i)
  • Pressure BioSciences's estimated revenue per employee is $134,615
  • Pressure BioSciences's total funding is $2M.

Employee Data

  • Pressure BioSciences has 26 Employees.(i)
  • Pressure BioSciences grew their employee count by 8% last year.

Pressure BioSciences's People

NameTitleEmail/Phone
1
Sr. VP EngineeringReveal Email/Phone
2
Chief Science OfficerReveal Email/Phone
3
Director Applications Development at Pressure BiosciencesReveal Email/Phone
4
Director OperationsReveal Email/Phone
5
Director Engineering, R&DReveal Email/Phone
6
Director Business DevelopmentReveal Email/Phone
7
President, CEO and DirectorReveal Email/Phone
8
Office ManagerReveal Email/Phone
9
Senior Manufacturing TechnicianReveal Email/Phone
10
Senior ConsultantReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Pressure BioSciences?

Following the sale of substantially all the assets and selected liabilities of its BBI Diagnostics and BBI Biotech Divisions to SeraCare Life Sciences, Inc. on September 14, 2004, Boston Biomedica, Inc. changed its name to Pressure BioSciences, Inc (PBI). PBI is a publicly traded, early-stage company focused on the development of a novel technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 4 foreign patents covering multiple applications of PCT in the life sciences field, including in such areas as genomic and proteomic sample preparation, pathogen inactivation, control of enzymes, immunodiagnostics, and protein purification. PBI owns a 30% passive investment in Source Scientific, LLC, an instrumentation company that develops and manufactures PBI\'s PCT equipment, as well as a passive investment of approximately 1 million shares in VI Technologies, an antiviral drug discovery and development company.

keywords:N/A

$2M

Total Funding

26

Number of Employees

$3.5M

Revenue (est)

8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Pressure BioSciences News

2022-04-20 - Head-To-Head Comparison: Pressure BioSciences ...

Head-To-Head Comparison: Pressure BioSciences (OTCMKTS:PBIO) versus Singular Genomics Systems (NASDAQ:OMIC). Posted by admin on Apr 27th, 2022.

2022-04-20 - Pressure BioSciences Announces Early Access Program for ...

Pressure BioSciences Announces Early Access Program for UST Nanoemulsion Processing ... SOUTH EASTON, MA / ACCESSWIRE / April 27, 2022 / Pressure...

2022-03-22 - Pressure BioSciences, Inc. to Discuss Fourth Quarter and Fiscal Year 2021 Financial Results and Provide Business Update

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6M260%N/A
#2
$4M26-13%N/A
#3
$1.7M27N/AN/A
#4
$5.1M27-4%N/A
#5
$6.2M270%N/A